TRUSOPT SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)

থেকে পাওয়া:

ELVIUM LIFE SCIENCES

এটিসি কোড:

S01EC03

INN (আন্তর্জাতিক নাম):

DORZOLAMIDE

ডোজ:

2%

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2%

প্রশাসন রুট:

OPHTHALMIC

প্যাকেজ ইউনিট:

5ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

CARBONIC ANHYDRASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0128558001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2016-11-02

পণ্য বৈশিষ্ট্য

_TRUSOPT_
_ ®_
_ (dorzolamide hydrochloride) _
_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRUSOPT
®
PR
TRUSOPT
®
PRESERVATIVE-FREE
Dorzolamide Hydrochloride Ophthalmic Solution
Solution, dorzolamide 2% weight/volume, Ophthalmic
Elevated Intraocular Pressure Therapy
(Topical Carbonic Anhydrase Inhibitor)
Elvium Life Sciences
3381 Steeles Avenue East, Suite 310
Toronto, ON
M2H 3S7
Date of Initial Authorization:
DEC 31, 1996
Date of Revision:
NOV 28, 2023
Submission Control Number: 274767
_ _
_TRUSOPT_
_ ®_
_ (dorzolamide hydrochloride) _
_Page 2 of 30_
RECENT MAJOR LABEL CHANGES
DOSAGE AND ADMINISTRATION, 4.4
Administration
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.4
Administration
.................................